熱門資訊> 正文

Pacira在将2025年收入调整至低于共识后股价下跌

2026-01-09 06:49

Pacira生物科學(PCRX) 0

Pacira BioSciences (PCRX) is down ~10% in after-hours trading Thursday after revising downwards its expectation for 2025 total revenues.
The company reported preliminary full-year revenues of $726.4M. Consensus is $730.22M.
Pacira also noted that during Q4, it repurchased 2M shares in the open market for $50M.

More on Pacira BioSciences

Pacira BioSciences, Inc. 2025 Q3 - Results - Earnings Call Presentation
Pacira BioSciences, Inc. (PCRX) Q3 2025 Earnings Call Transcript
Pacira BioSciences: Generics Are Coming For The Crown Jewel
Pacira reports preliminary FY25 revenue of $726.4M
DOMA Perpetual Capital to offer nominees for Pacira BioSciences board

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。